About Notch Therapeutics
Notch Therapeutics is a Healthcare company based in Toronto (Canada) founded in 2018 by Shreya Shukla. Developer of stem-cell derived immune cell therapies. Notch Therapeutics has raised $100.5 million across 2 funding rounds from investors including Allogene, Lumira Ventures and CCRM. The company has 75 employees. Notch Therapeutics offers products and services including UNi-T Cell. Its focus areas include Life Sciences, Oncology, Drugs and Diversified.
Company details
Developer of stem-cell-derived immune cell therapies. The proprietary Engineered Thymic Niche (ETN) platform enables the expansion and differentiation of induced pluripotent stem cells (iPSCs) are fully defined, feeder-free, and serum-free cultures into mature T cells and other types of immune cells.
- Headquarters Toronto, Canada
- Employees 75
- Founders Shreya Shukla
- SectorsHealthcare
- Website notchtx.com
- Social LinkedIn
- Total Equity Funding$100.5M (USD)
in 2 rounds
- Latest Funding Round$15.5M (USD), Series A
May 2024
- InvestorsAllogene
& 6 more
- Employee Count75
Products & Services of Notch Therapeutics
Notch Therapeutics offers a comprehensive portfolio of products and services, including UNi-T Cell.
Off-the-shelf T cell therapy for adoptive cell therapy in cancer.
Funding Insights of Notch Therapeutics
Notch Therapeutics has successfully raised a total of $100.5M across 2 strategic funding rounds. The most recent funding activity was a Series A round of $15.5 million completed in May 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $100.5M
- Total Rounds 2
- Last Round Series A — $15.5M
- First Round $85M
(Feb 2021)
- Investors Count 7
All 2 funding rounds of Notch Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May 2024 | $15.5M | Series A | – | – | – |
| Feb 2021 | $85M | Series A | – | – |
7 investors in total: 7 institutional.
Investors in Notch Therapeutics
Notch Therapeutics has secured backing from 7 investors, including institutional and venture fund investors. Prominent investors backing the company include Allogene, Lumira Ventures and CCRM.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Lumira Ventures is engaged in life sciences venture capital investment. | lumiraventures.com | Toronto, Canada | ||
Venture capital funding is provided by Samsara BioCapital in California. | samsaracap.com | Palo Alto, United States | ||
Investing in Life Sciences sectors like Healthcare and Biotechnology. | casdincapital.com | |||
Venture capital investments are made in precision medicine companies. | amplitudevc.com | Montreal, Canada | ||
Chimeric antigen receptor cell therapies for cancer treatment are developed. | 2018 | allogene.com | San Francisco, United States | |
CCRM is engaged in commercializing regenerative medicine and cell therapies. | ccrm.ca | Toronto, Canada | ||
| ecor1cap.com |
Investor details for Notch Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Notch Therapeutics
1 people are tracked at Notch Therapeutics (1 in leadership); the tracked headcount is 75.
| Name | Role | Group |
|---|---|---|
Shreya Shukla | Founder | Leadership |
Complete people profiles for Notch Therapeutics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Notch Therapeutics
3 dated milestones of Notch Therapeutics across 6 years, from founding to its latest funding, stage changes and deals.
- Founded Notch Therapeutics is founded.
- Funding First funding round of $85.0M.
- Funding Latest funding round, Series A, of $15.5M.
Web traffic of Notch Therapeutics
Websites that share an audience with Notch Therapeutics (notchtx.com).
Websites whose visitors overlap most with Notch Therapeutics. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| ccrm.ca | 100% | #3,718,695 | View details |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Notch Therapeutics
Complete news archive for Notch Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Notch Therapeutics
Notch Therapeutics was founded in 2018 and raised its 1st funding round 3 years after it was founded.
Notch Therapeutics is headquartered in Toronto, Canada. It is registered at Toronto, Ontario, Canada.
Notch Therapeutics is a funded company, having raised a total of $100.5M across 2 funding rounds to date. The company's 1st funding round was a Series A of $85M, raised on Feb 2021.
Notch Therapeutics has 75 employees.
Developer of stem-cell-derived immune cell therapies. The proprietary Engineered Thymic Niche (ETN) platform enables the expansion and differentiation of induced pluripotent stem cells (iPSCs) are fully defined, feeder-free, and serum-free cultures into mature T cells and other types of immune cells.
Notch Therapeutics offers UNi-T Cell.
Notch Therapeutics has 7 investors. Key investors include Allogene, Lumira Ventures, CCRM, EcoR1, and Samsara BioCapital.